Prognostic value of dipyridamole thallium scintigraphy for evaluation of ischemic heart disease  by Hendel, Robert C. et al.
Coronary artery disease is the 
and mortality in the United St 
ever, this invasive technique has potential risks and substan- 
tial costs that diminish its utility as a screening procedure for 
the general population. Additionally, even if coronary artery 
disease is detected by catheterization, the indications for 
revascularization in asymptomatic patients or those with 
stable angina pectoris are unclear. 
Exercise testing either alone or with radionuclide imaging 
provides many diagnostic and prognostic data (2-15) and 
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either exercise-induced or pharmacologic vasodilation. A 
persistent defect on serial thallium scans suggests nonviable 
myocardium or scar. However, redistribution o  thallium 
scintigraphy is a marker of potentially ischemic myocardium 
(16). Thallium imaging after the administration f the coro- 
nary vasodilator dipyridamole has been demonstrated to 
detect coronary artery disease (U-22) and is diagnostically 
equivalent to perfusion studies performed after maximal 
exercise (21-23). This technique has also been used to 
evaluate cardiac risk in patients undergoing elective vascular 
surgery (24-29) and to predict future cardiac events after 
myocardial infarction (30). 
In contrast to exercise stress testing, y~damo~e thal- 
lium scintigraphy is not dependent on the level of exertion 
achieved, patient motivation or concurrent a~tiang~~al med- 
ications (18, 19). It is widely applicable for the detection and
assessment of coronary artery disease; however, its utility in 
the general population is unknown. The aim of this study 
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was to evaluate the potential clinical utility of dipyridamole 
thallium imaging in a large unselected patient population. 
Our hypothesis i that an abnormal thallium scan carries an 
increased risk of subsequent major cardiac events (myocar- 
dial infarction or cardiac death: and that the presence of 
redistribution thallium scintigraphy further increases the 
relative risk of a cardiac event. 
Study patients. All 516 patients referred to the University 
of Massachusetts Medical Center for the performance of
dipyridamole thallium scintigraphy during the 3 year period 
between January 1, 1983 and December 31, 1985 were 
analyzed in a retrospective fashion. Reasons for the dipyr- 
idamole thallium scanning included preoperative evaluation 
in patients undergoing vascular surgery, medical evaluation 
of chest pain or other symptoms possibly related to ischemic 
heart disease, as well as the assessment of myocardial 
revascularization. A history of prior myocardial infarction 
was reported when diagnostic abnormalities (i.e., Q waves) 
were present onthe electrocardiogram !ECG). 
Dipyridamole thallium scintigraphy. Dipyridamole thal- 
lium imaging was perfor;ned according to a previously 
dess&zd protocol (26). EtieBji, di:: patients ‘were studied in 
the fasting state with all theophylline-containing medications 
being withheld for 236 h. Under continuous ECG monitor- 
ing and with frequent blood pressure assessment, the patient 
was given intravenous dipyridamole (Boehringer-lngelheim, 
Inc.) at a rate of 0.56 m&kg body weight over 4 min. 
Thallium-201 ( .5 to 2.5 mCi) was administered 3 to 4 min 
after the infusion of dipyridamole. The occurrence ofsymp- 
toms was noted uring and after the dipyridamole infusion 
and parenteral minophylline was available for the reversal 
of any adverse effects. 
Images were acquired m the anterior and 45” and 70” left 
anterior oblique views for 7 min per view on a standard 
gamma camera equipped with a high resolution collimator in 
a 128 X 128 matrix. Similar views were repeated 2.5 to 4 h 
later. Each scan was qualitatively analyzed by one of three 
staff nuclear cardiologists. The scans were divided into nine 
segments (three segments per view) and were read as normal 
or abnormal: abnormal scans were further classified as 
demonstrating persistent or transient defects, or both, as 
previously described (19). Transient defects were further 
subdivided into those with single segment redistribution r
multiple segment redistribution. 
Follow-up. Follow-up information was obtained in 504 
(98%) of the 516 patients by telephone contact with the 
patient or family member. Medical records, as well as 
information obtained from the referring physician, were used 
for patients who were not personally contacted. Follow-up 
was considered complete if ~10 months of information was 
obtained or the patient died. Clinical follow-up end points of 
the study included: I) death classified as cardiac or noncar- 
disc on the basis ofmedical records and death certificates; 2)
myocardial infarction, confirmed by review of ECGs and 
serum enzyme criteria obtained from medical records; 3) 
continued chest pain; 4) cardiac atheterization; 5) coronary 
artery bypass graft surgery; and 6) percutaneous translumi- 
nal coronary angioplasty. Only the major end points of 
cardiac death or myocardial infarction were considered for 
logistic regression analysis. 
. Fisher’s exact t test was used to 
variables from the patient population 
to determine the significance of di rences in the rates of 
cardiac events. Final results are expressed as mean valu 
SD. A nonlinear stepwise logistic regression analysis ( 
DPLR Health Sciences Computing Facility, University of 
California, Los Angeles) was used to determine the statisti- 
cal value for the prediction of cardiac death or myocardial 
infarction, or both, by the various clinical and scintigraphic 
variables. Product limit survival analysis of cardiac events 
for groups with abnormal and ormal scans was also per- 
formed. 
Patient chsracteristics. Complete follow-up info 
was available for 504 (98%) of the 516 patients who under- 
went dipyridamole thallium scintigraphy during the 3 year 
study period, The average follow-up interval was 21 +- 8 
months. A total of 52 patients (10%) experienced a major 
cardiac event, defined as either myocardial infarction or 
cardiac death. There were 43 cases of myocardial infarction 
during this period and 23 deaths of cardiac origin. 
Table I shows the clinical data for 1111504 patients, as well 
as the distribution ofclinical variables among those who had 
acardiac event (n = 52) and those who did not (n = 452). The 
mean age for all patients was 64 f I l years: those who had 
a cardiac event during the follow-up period were signifi- 
cantly older. The presence of diabetes mellitus and a history 
of congestive heart failure or myocardial infarction were 
noted more frequently inpatients who experienced a cardiac 
event han in those who did not. A large percentage of the 
subjects had a history of hypertension (52%), angina pectoris 
(63%) or peripheral vascular disease (34%). However, these 
factors as well as the incidence of valvular heart disease 
were not significanlly distributed among patients based on 
future events. The use of various medications and the 
reasons for Leferral were not significantly different between 
the groups with and without a cardiac event. 
Mpyridamole thallium schtigraphy. Figure I illustrates 
the classification of dipyridamole thallium scans as either 
normal or abnormal in the 504 patients. Of the 332 abnormal 
scans, 249 (75%) demonstrated redistriburtion and 83 (25%) 
demonstrated only persistent abnormaiities. The scans with 
transient abnormalities were further subdivided into whether 
Cardiac No Cardiac 
Event Event 
tn = 52) dn = 452) p Value 
Age (yr -’ SD) 
Male 
Reason for referral 
Preoperative assessment 
edical evaluation 
Diabetes rnelfitus 
~y~~ensioo 
Angina pectoris 
Congestive heart failure 
Valvular disease 
Peripheral vascu;ar disease 
Previous infarction 
edications 
Digoxin 
Diuretic 
5et~a~re~ergi~ blocking agent 
Nitrates 
Calcium channel biocking agent 
Antiarrhythlnic agent 
22 (421 84 ( !9) 
31 (60) 230 (511 
3ir6w 2x-l (641 
7 (141 19 (41 
2 (4) 9 I!) 
21 MOO) ISI (33) 
26 (50) “44 (341 
7 (84) 
20 (391 
17 i331 
23 1441 
!4 !2?) 
5 (10. 
0.5714 
0.2302 
0.9205 
0.5%5 
0.1778 
Ab~o~rn~ Scan 
(n = 339 L 
38 (921 
?I (6) 
195 (59) 
53 (16) 
25 (8) 
4(l) 
18 (51 
p Value 
0. 
0. 
0. 
0. 
~.~249 
0.9670 
0.6651 
Figures in parentheses indicate percent of patients. 
I- -- 
Figures in pareothese* indicate percent eF gatienir; 
or not 
249 scans; the 
3 transient a~~or~a~ity. 
Table 2 summarized the c~i~icQ1 ~~f~~~~-~~p daaa an 
zatton and co~o~~y 
re 1. Results of dipyridamole tha ium sci~~ig~p~y in 516 
pattents over a 3 year period (1983 lo I 
516 
12 (2%)/‘504 (98%) 
without with 
Follow-Up Follow-Up 
/\ 
172 (34%) 332 (66%) 
Normal Abnormal 
Scan Scan 
/\ 
63 249 (75Yq 
Per~;syt (25%) Redistributwxt 
74 ‘3cl%{’ 175 (70%) 
1 se;ment )l Segment 
Table 3. Results of Qipy~damo~e Thallium Scinti 
Cardiac No Cardiac 
Evwt Event 
(n = 59 (n = 452) p Value 
Normal scan 7 (14) 
Abnormal scan 45 (871 
Redistribution > I seg 30 Lw 
Redistribution = I seg 4 (81 70 (16) 5.1?31 
37 (71) 202 (45) 0. 
17 (331 JBJ (36) 0. 
Chest pain 7 114) g1 (181 0. 
Ischemic. KG changes 6 (I?) 31 (7) Q.2212 
Other 12 (231 i 
Am~no~hy~li~e required 12 (23) 75 (17) a.2422 
Figures in parentheses indicate percent of patients. ECG = electrocardio~ 
gmphic: seg = segment. 
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Table 4. Predictive Vaiue of Various Clinical Variables 
MUI Cardiac Events Myocardial Infarction Cardiac Death 
Variable p Value* Relative Riskt p Value* Relative Riskt p Value* 
Abnormal scan 0.0004 3.1 O.Ooa4 3.6 0.0034 
Congestive heart failure 0.0137 3.0 0.0776 0.0044 
Diabetes mellitus 0.0002 2.8 0.0000 4.1 0.6540 
Gender 0.0834 0.2535 - 0.0081 
Prior myocardhl infarction 0.0254 0.1283 - 0.0991 
Peripheral vascular disease 0.3204 0.2701 - 0.3413 
*p values reflect values from step 0 of regression analysis: trelative risk refers to odds ratio after completion of regression model. 
Relative Risk? 
3.9 
5.4 
- 
0.4 
reactions between those patients who did and did not expe 
rience a cardiac event during the follow-up eriod. 
&ogne&ic value. Three separate stepwise nonlinear re- 
gression analyses were performed Eo evaluate the prognostic 
significance of several clinical (Table 1) and scintigraphic 
(Table 3) variables and their value in the prediction of late 
myocardial infarction or death. At each step, the variable 
with the highest chi-square value was entered into the mode! 
until no variable had a p value CO. 10. Six variables (diabetes 
mellitus, abnormal dipyridamole thallium scan, history of 
congestive heart failure, prior myocardial infarction, gender 
and peripheral vascular disease) were chosen for analysis of
tirdir predictive value, based on the two-tailed t test, as well 
as after a preliminary, low precision logistic regression 
analysis that evaluated all potential predictors. 
The results of regression analysis aresummarized in 
Table 4. An abnormal scan, history of congestive heart 
failure, diabetes mellitus and previous myocardial infarction 
were independent predictors of a late cardiac event (p < 
O.OS), the first three variables having approximately equal 
significance in the predicting model. In another egression 
analysis evaluating the variables for cardiac death alone, the 
best predictors were a history of congestive h art failure and 
an abnormal thallium scan; male gender added minimal 
statistical improvement to the model beyond the first two 
variables alone. In the third analysis, diabetes mellitus and 
an abnormal scan were the only two predictors included in 
the model for predicting future myocardial infarction. 
From these regresolon analyses (Fig. 2), the predicted 
probability of a cardiac event in patients with a normal 
dipyridamole thallium scan was determined to be 3 -C 1%. 
An abnormal scan raised the predicted probability o9 * 2% 
and the addition of diabetes mellitus or congestive heart 
failure raised it to 22 f 4% or 23 5 8%, respectively. The 
combination of diabetes mellitus, congestive heart failure 
and an abnormal dipyridamole thallium study resulted in the 
highest predicted probability of having amyocardial infarc- 
tion or cardiac death (46 + 12%), and raised the relative risk 
of a cardiac event more than 26-fold. 
Because the finding of an abnormal scan was an important 
vedictor of subsequent events in this popuiation, an addi- 
tional regression analysis was performed to determi~c 
whether any scintigraphic variables were of further prognos- 
tic utility in patients with an abnormal scan. The presence of
more than one segment demonstrating redistribution on 
dipyridamole thallium scintigrams was a significant indepen- 
dent predictor of total cardiac events. The relative risk for a 
late cardiac event of patients with an abnormal scan and 
presence of redistribution was increased an additional 2.4- 
fold and the predicted probability for a cardiac event was 10 
4 3% in this group. Persistent perfusion ab~o~alities on the 
scan also added an additional significant improvement to the 
model by increasing the predicted probability o 22 + 4% in 
patients with both transient and persistent abnormalities. 
When the scintigraphic variables in all patients were exam- 
ined with logistic regression analysis, the presence of redis- 
tribution was n ~~~e~e~de~~t pr dictor of a cardiac event (p 
= 0. ) and more than doubled the risk of a myocardial 
infarction or cardiac death. 
As assessed by product limit analysis (Fig. 3), an abnor- 
mal scan confers astatistically significant decrease in event- 
free survival (without myocardial infraction or cardiac 
Fii~+ 2. Comparison f predicted (solid bsr, with 1 SD) and 
observed (open bar) probabilities of experiencing a myocardial 
infarction r cardiac death based on the presence of various factors. 
ABN = abnormal thallium scan; CHF = history of congestive h art 
failure; DM = diabetes mellitus; NL = normal thallium scan. There 
were no observed cardiac events in patients having only a history of 
congestive heart failure (0%). 
NL DM CHF ABN ABN A9N 
+LM +?:F +DM 
+CHF 
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Months 
re 3. Life table analysis c~~pa~~~ the event-free survivai of !72 
patients with a normal dipyridam 
that of 332 patients with an abno 
death or myocardial infarction occ 
with an abnormal dipyrida~ole thallium stint 
survival analysis (p = 0.12). 
s add~t~o~a~~y elevates the relative 
An abnormal scan is associate 
ofmyocardial infarction, cardiac 
death and combined events, as well as of recurrent angina, 
the performance of cardiac atheterization r coronary ar- 
tery bypass graft surgery. Although recurrent angina may be 
a marker of ischemia, the subjective nature of this symptom, 
as well as influence by medication usage and other factors, 
makes this a potentially unreliable end point of prognostic 
testing. Furthermore, the decision to perfotm coronary 
arte~ography and subsequently coronary artery bypass graft 
surgery is frequently influenced by individual physicians’ 
biases and may also be affected by the presence of abnormal 
findings on dipyridamole thallium scintigraphy. T 
only the “hard” end points of 
myocardial infarction were consi 
the predictive value of di~y~damole thallium imaging. 
The factors elected for logistic regression analysis were 
inary statistical fi
impo~ant variables. 
sion analysis including all clinical and scintigraphic variables 
failed to reveal any new variables that chieved statistical 
significance. The perfusion studies were grouped as abnor- 
associated with a 
nto the prediction of 
strated a sig~~~ca~t 
more than one segment of thallium redistribution had inde- 
pendent predictive v for myocardial infarction and for 
total cardiac events. tiple transient thallium abnormali- 
ties were noted in 35% of the study population and was the 
scintigraphic variable that placed these patients at the high- 
est risk for a subsequent cardiac event. Although the pres- 
ence of persistent abnormalities added to the predicted 
accuracy of the model, this variable was not of i~depe~deat 
significance. Interestingly, the presence of nly one segment 
of redistribution appeared to be associated with an event- 
free follow-up. This may reflect an interpretation artifact 
caused by a relatively ow threshold for abnormal segments 
by the observers. Therefore, small ntal scan “abnor- 
malities” that are typica~iy subtle an 
to have little predictive value for subsequent cardiac events. 
A normal dipyridamolt f~~~~ii~~~ scan co&erred Q good 
prognosis and identified 34% of the subgroup opulatiou 
who were at a low risk for myocardial nfarction or cardiac- 
related eath. These results are consistent with previous 
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reports (24-30) regarding the prognostic utility of dipyrid?n- 
ofe thallium imaging in specifically defined popui-uions. 
However, our study was not limited by reasons of referral 
and was performed in essentially an unselected popukition. 
An additional advantage over these earlier studies, espe- 
cially those in patients undergoing vascular surgery, was that 
extended follow-up information was available. 
comparison whh exercise Perfusion imaging  
conjunction with exercise tes shown good results in 
detecting coronary artery disease and has excellent prognos- 
tic utility (2-13,33). Data from these studies may add to and, 
in many cases, supplant cardiac atheterization data (2- 
4,33). It has been shown that patients with a normal thallium 
scintigram have an excellent prognosis 
dence of myocardial infarction or ca 
(11.12). Even in the presence of diabetes m llitus, anormal 
scan was a predictor of significantly fewer events (9). 
Abnormal results of thallium exercise scintigraphy por- 
tend a poor prognosis and a ntly increased risk of 
further cardiac events (5-9). nally, the presence, 
location or amount of thalli ution during exercise 
imaging has been shown to graphic variable with 
the most prognostic utility in relation to future myocardial 
infarction (3-5,33); it also has significant predictive power 
for all cardiac events (2,3,10,33). Exercise testing, however, 
is often limited by the inability of patients to achieve a 
suflicient level of exertion. 
In contrast, dipyridamole thallium scintigraphy is unaf- 
fected by patient motivation or medications and can be 
performed inpatients who are otherwise not able to undergo 
maximal exercise testing because of limitations imposed by 
peripheral vascular disease, pulmonary disorders or muscu- 
loskeletal bnormalities. Dipyridamole thallium imaging also 
does not require a substantial ncrease inmyocardial oxygen 
consumption, and the effects of coronary hyperemia, unlike 
those of exercise, may be quickly and completely reversed 
(1821). 
Safety and side effects. Aminophylline was required in 
17% of the patients undergoing dipyridamole thallium testing 
in the present setting, all of whom had no lasting sequelae. In
other studies, the safety of dipyridamole thallium testing in 
this type of population is suggested bythe fact that only one 
death has been reported (34) and serious adverse reactions 
are exceedingly rare (19-21,35,36). The frequency of side 
effects in our study was similar to that reported in these 
other studies; the majority consisted ofheadache, nausea or 
dizziness. No life-threatening reactions occu i in our 
Patients in more than 500 procedures. Chest pain occurred in
18% of patients during the procedure (this incidence rate was 
at the tow errd of the reported range [18% to 43%]) and 
demonstrated no prognostic value, confirming similar obser- 
vations noted in smaller study groups (37). ST segment 
depression, recorded infrequently i  our subjects (7%). was 
also not of predictive utility, a finding consistent wit 
previous tudies (19,27,30). 
C pli~~~on~. In an earlier study (30), dipy~dam- 
ole t canning was demonstrated to be predictive of 
cardiac events after acute myocardial infarction. The pres- 
ence of redistribution markedly increased the risk of a late 
(19 months) cardiac event, a tinding that was co&rned by 
our present study. The majority of prior reportci (24-29) 
demonstrating the prognostic value of dipyridamole thallium 
imaging have been collected in patients undergoing preoper- 
ative assessment before vascular su . When these short- 
term studies are pooled, 29% s with transient 
perfusion abnormalities after di e admi~~stI~ti0~ 
had a perioperative myocardial infarction or cardiac-related 
death, as compared with I% of patients without hallium 
redistribution. The present study is in agreement with these 
conclusions and further demonstrates that an abnormal scan 
increases the risk that apatient will experience subsequent 
myocardial infarction or death. The independent predictive 
value of this imaging procedure is iurther enhanced by the 
presence of thallium redistribution. 
ens. Our study has several limitations. Altbougb 
it does not allow direct comparison between dipy~d~ole 
thallium imaging and thallium scanning after exercise, pre- 
vious studies of dipyridamole thallium scintigraphy have 
shown similar diagn.ostic a curacy for this procedure (21.22). 
Because angiographic information is not available, our study 
rrnit assessment of the specificity and sensitivity 
of dipyridamole thallium ~e~~sio~ imaging or comparison of
cardiac catheterization w th thallium scintigraphic f ndings. 
An additional problem is the lack of quantification f thal- 
lium scintigraphic findings. Such quantification may yield 
additional prognostic information (3,4,7,10,13). Although 
qualitative interpretation f the thallium scans has been 
shown to be of high diagnostic (19,21,22) and prognostic 
(27-30) utility, quantitative analysis of the thallium scinti- 
grams may enhance their usefulness (38). Single photon 
emission computed tomography may also improve resolu- 
tion and further increase the diagnostic value of dipyridam- 
ole thallium perfusion studies (39,40). 
Conclushs. Dipyridamole thallium imaging has long- 
term prognostic utility in evaluating patients uspected of
having coronary artery disease as well as those undergoing 
an elective surgical procedure. This technique may be used 
as an initial procedure to screen for the presence of signifi- 
cant coronary artery disease, regardless of the patient’s 
symptoms. Those with an abnormal scan may well be 
advised to undergo additional evaluation. As in the present 
study, it would be possible to classify the majority of 
patients as being at either high or low risk for myocardial 
infarction or cardiac death. Overall, perfusion imaging after 
dipyridamole infusion appears to be an effective way to 
determine prognosis without the use of physiologic exercise 
and may be an acceptable alt rnative procedure in many 
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